FDA: Page


  • Billion-dollar settlement gets Reckitt out of federal opioid probes

    Company spinout Indivior, however, is still facing criminal charges related to marketing of Suboxone film, an opioid dependence treatment. 

    By • July 11, 2019
  • White House pulls drug rebate rule to relief of payers

    Withdrawal of the rule, which drugmakers supported, puts greater focus on the administration's plans for an international price index for certain drugs.

    By Ned Pagliarulo • July 11, 2019
  • In win for pharma, Trump TV drug price rule struck down

    The federal district court sided with drugmakers, which argued the government overstepped its authority in forcing price transparency in advertisements.

    By • July 9, 2019
  • BioMarin confirms timeline for hemophilia gene therapy, putting pressure on rivals

    The biotech plans on submitting valrox to U.S. and European regulators in the fourth quarter, which could bring approval decisions by mid-2020.

    By • July 8, 2019
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    BioPharma Dive's 10 biggest stories of the spring

    Developments in gene therapy, cancer treatments, drug pricing and dealmaking kept the industry in the headlines.

    By • July 3, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA set for 'exceptionally light month' of generic drug approvals in June

    After generic drug approvals by the FDA hit all-time highs last year, one Wall Street analyst wonders if June data shows the start of a slowdown.

    By Andrew Dunn • June 28, 2019
  • Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Amgen bone drug application knocked back in Europe

    While both the U.S. and Japan have approved Evenity, the EMA's drugs committee judged its heart risk didn't outweigh its potential benefit.

    By Ned Pagliarulo • June 28, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Zogenix boosted on FDA about-face for seizure drug application

    The regulator agreed to permit resubmission of Zogenix's drug with a corrected dataset, while waving off a potentially time-consuming toxicology study.

    By • June 27, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Federal court bars stem cell sales by Florida company in win for FDA oversight

    FDA leaders Ned Sharpless and Peter Marks said the legal action "sends a strong message to others manufacturing violative stem cell products."

    By Andrew Dunn • June 27, 2019
  • AbbVie deal for Allergan not about the taxes, thanks to 2017 law

    AbbVie will stay in the U.S. if its deal goes through — a departure from Pfizer's plan in a failed 2015 attempt to merge with the Ireland-based Allergan.

    By • June 26, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA officials see 'missed opportunity' with patient outcomes in clinical trials

    The information is viewed as a valuable tool for improving trial design, guiding drug approvals and supporting label decisions, but its reach has been limited.

    By • June 26, 2019
  • Bristol-Myers price for Celgene now includes Otezla sell-off

    A Federal Trade Commission review spurred the divestiture plan, as the combined company would otherwise have two marketed drugs and one experimental project in inflammatory disease.

    By • June 24, 2019
  • A photo of AbbVie's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    FDA lifts hold on AbbVie multiple myeloma study

    However, nine other studies for Venclexta remain suspended for safety concerns.

    By Andrew Dunn • June 24, 2019
  • Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Merck racks up another FDA approval for Keytruda cancer drug

    The blockbuster immunotherapy wins its first approval for treating small cell lung cancer.

    By Kristin Jensen • June 18, 2019
  • FTC demands could mean months-long delay for Roche-Spark deal

    A rare "second request" for info on Roche's cash buyout tasks both companies with providing extensive documents and executive testimony.

    By • June 12, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA weighs role of high-dose opioids as two-day expert meeting begins

    Amid a nation-wide epidemic of addiction and overdose, the agency is considering whether highly potent opioids have a place in the healthcare system.

    By Andrew Dunn • June 11, 2019
  • Image attribution tooltip
    Roche
    Image attribution tooltip

    Roche wins speedy OK for lymphoma drug Polivy

    Polivy is approved in a similar setting as Gilead's Yescarta, adding a new option for lymphoma patients whose cancers are relapsed or refractory to treatment. 

    By Ned Pagliarulo • June 11, 2019
  • NASH drugmaker stocks rebound after dip on FDA guidance

    Madrigal, Viking, Intercept and GenFit each saw small gains Monday, as investors appeared less concerned about new FDA guidance on approval standards for certain NASH drugs.

    By • June 10, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA's Woodcock defends accelerated approvals and talks of culture shift in clinical trials

    In a wide-ranging interview, CDER chief Janet Woodcock pushed back against concerns the agency is clearing new drugs too quickly. 

    By Andrew Dunn • June 5, 2019
  • A piece of DNA stretches vertically along a plain background.
    Image attribution tooltip
    Getty / Edited by BioPharma Dive
    Image attribution tooltip

    Bluebird gene therapy approved in Europe in first for severe blood disorder

    Zynteglo is intended as a one-time, lifelong treatment for patients with transfusion-dependent beta thalassemia. 

    By Ned Pagliarulo • June 3, 2019
  • Image attribution tooltip
    ASCO / Scott Morgan
    Image attribution tooltip

    At cancer conference, debate over speedy drug approvals in the spotlight

    An unsuccessful Phase 3 study of Eli Lilly's Lartruvo made for an unusual feature in the ASCO annual meeting's top trial showcase.

    By Ned Pagliarulo • June 3, 2019
  • Mitsubishi pulls EU application for ALS drug, citing 'unwarranted' data request

    Regulators had concerns that data from a key study that has helped Radicava in other markets isn't strong enough to warrant approval in the bloc.

    By • May 31, 2019
  • Image attribution tooltip
    Ryan McKnight, Vertex Pharmaceuticals Inc.
    Image attribution tooltip

    Vertex chooses its cystic fibrosis future

    Following positive late-stage readouts for two combination regimens, Vertex has selected the triplet it intends to file with regulators later this year.

    By • May 30, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Epizyme moves forward with cancer drug, eyes 2020 launch

    The biotech is seeking an accelerated approval from the FDA for tazemetostat, an experimental treatment for a rare, aggressive tissue cancer.

    By Andrew Dunn • May 30, 2019
  • Sponsored by ZS

    How to survive in pharma's payer-empowered world

    Success in the new payer-empowered world of value and affordability requires two fundamental changes in pharma companies’ corporate decision-making.

    By Ed Schoonveld • May 30, 2019